A Review of Available Medical Therapies to Treat Moderate to Severe Inflammatory Bowel Disease in 2023

The treatment armamentarium for inflammatory bowel disease (IBD) has expanded rapidly in the past several years with new biologic and small molecule agents approved for moderate to severe ulcerative colitis and Crohn’s disease. This has made treatment selection more challenging with limited but evolving guidance as to where to position each medication. In this review, we discuss the efficacy data for each agent approved in the United States by reviewing their phase III trial data and other comparative effectiveness studies. Additionally, safety considerations and use in special populations is summarized with proposed algorithms for positioning therapies. The aim is to provide a synopsis of high impact data and aid in outpatient treatment decision making for IBD patients.